Analytical Strategies for Impurity Characterisation

Impurity Profiling and Forced Degradation

Analytical Strategies for Impurity Characterisation

Impurity profiling typically begins with a validated stability-indicating chromatographic method capable of resolving and quantifying individual impurities against a reporting threshold. Impurities present above the identification threshold require structural elucidation, commonly achieved through a combination of liquid chromatography coupled with high-resolution mass spectrometry to establish elemental composition and fragmentation behaviour, nuclear magnetic resonance spectroscopy to establish detailed structural connectivity, and, where necessary, isolation of the impurity by preparative chromatography to obtain enough for comprehensive characterisation. Structural elucidation is frequently supported by an understanding of plausible synthetic and degradation mechanisms, which allows the analyst to propose and subsequently confirm probable impurity structures.

Impurity profiling is the process of detecting, identifying, isolating, and characterizing impurities present in a pharmaceutical drug. It helps ensure the quality, safety, and effectiveness of medicines.

What happens?

First, impurities are detected and measured using analytical techniques.

Common Techniques

  • HPLC
  • UHPLC
  • GC
  • LC-MS

Purpose

  • Detect impurities
  • Measure impurity levels
  • Check if impurities are within acceptable limits

What is Structural Elucidation?

It is the process of determining the chemical structure of an unknown impurity.

LC-MS / HRMS

  • Determines molecular weight.
  • Provides molecular formula.
  • Helps identify unknown compounds.

NMR Spectroscopy

  • Determines the arrangement of atoms.
  • Confirms the chemical structure.

Isolation

  • Separates the impurity from the drug.
  • Obtains a pure impurity sample for analysis.

Structure Assignment

  • Combines all analytical data.
  • Confirms the final impurity structure.

The impurity analysis follows these steps:

1. Sample Preparation

  • Prepare the drug sample for analysis.

2. Chromatographic Analysis

  • Separate impurities using HPLC or GC.

3. Screening

  • Detect impurity peaks using PDA or MS.

4. Structural Elucidation

  • Identify the impurity using LC-MS, NMR, and IR.

5. Isolation (if required)

  • Collect the impurity in pure form.

6. Confirmation and Documentation

  • Confirm the structure and prepare the analytical report.

1. Method Development

Develop a stability-indicating analytical method that can separate the drug from all impurities.

2. Sensitivity

The analytical method should detect impurities at very low concentrations (typically ppm or lower).

3. Analytical Techniques

Common techniques include:

  • HPLC
  • GC-MS
  • LC-MS/MS
  • HRMS
  • NMR
  • FTIR

4. Sample Handling

  • Prevent contamination.
  • Use appropriate storage conditions.
  • Minimize sample degradation.

5. Isolation Strategy

Choose a suitable chromatographic method to obtain a pure impurity before structural analysis.

6. Data Quality

Ensure:

  • Accurate results
  • Good peak resolution
  • Proper system suitability
  • Reliable spectral interpretation

7. Documentation

Maintain:

  • Raw data
  • Chromatograms
  • Spectra
  • Calculations
  • Complete analytical reports

8. Regulatory Compliance

Follow regulatory guidelines such as:

  • ICH Q3A – Impurities in New Drug Substances
  • ICH Q3B – Impurities in New Drug Products
  • ICH M7 – Assessment of Mutagenic Impurities
  • ICH Q2(R2) – Analytical Method Validation

Modern impurity profiling uses advanced technologies such as:

  • High-Resolution Mass Spectrometry (HRMS)
  • Ultra-High Performance Liquid Chromatography (UHPLC)
  • LC-MS/MS
  • Automated sample preparation
  • Artificial Intelligence (AI) for impurity prediction

These techniques improve the speed, accuracy, and sensitivity of impurity analysis.

AI is increasingly used to:

  • Predict impurity formation pathways.
  • Identify unknown impurities.
  • Analyze complex chromatographic and spectral data.
  • Improve data interpretation.
  • Support faster decision-making during pharmaceutical development.

Future developments in impurity profiling include:

  • Integrated analytical platforms.
  • AI-assisted impurity identification.
  • Real-time Process Analytical Technology (PAT).
  • Automated impurity monitoring.
  • More efficient risk assessment and quality control.

  • Ensures drug safety.
  • Improves product quality.
  • Meets regulatory requirements.
  • Supports method development.
  • Reduces manufacturing risks.
  • Protects patient health.

Key Takeaway

Detection, isolation, and structural elucidation of impurities are essential steps in pharmaceutical quality control. Impurities are first detected and quantified using chromatographic techniques, then identified using advanced analytical tools such as LC-MS, NMR, and FTIR. Proper impurity profiling ensures that pharmaceutical products meet regulatory standards, remain safe and effective, and maintain consistent quality throughout their lifecycle.

Genotoxic impurity analysis frequently requires exceptionally sensitive analytical techniques, such as gas chromatography or liquid chromatography coupled with tandem mass spectrometry, capable of reliably quantifying impurities at parts-per-million levels relative to the drug substance, reflecting the very low permitted exposure limits applicable to such impurities.

Computational toxicology tools, including quantitative structure-activity relationship models, are increasingly employed to assess the mutagenic potential of impurities lacking experimental toxicological data, supporting risk-based control strategies consistent with International Council for Harmonisation M7, while high-resolution mass spectrometry combined with automated data mining software is accelerating the detection and structural annotation of unknown impurities within complex chromatographic datasets.